SCRI Tissue Testing Registry

This study has been terminated.
(Replaced by a study with a similar design.)
Sponsor:
Information provided by (Responsible Party):
SCRI Development Innovations, LLC
ClinicalTrials.gov Identifier:
NCT00965861
First received: August 24, 2009
Last updated: August 27, 2013
Last verified: August 2013

August 24, 2009
August 27, 2013
May 2010
February 2013   (final data collection date for primary outcome measure)
  • To establish an electronic registry to store information from patients who have provided their consent allowing use of their tissue sample(s) for future testing. [ Time Frame: 120 months ] [ Designated as safety issue: No ]
  • To perform testing on the tissue samples to learn more about specific types of cancer and/or other diseases [ Time Frame: 120 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00965861 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
SCRI Tissue Testing Registry
SCRI Tissue Testing Registry

Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

This study will consist of a registry of patients who have agreed to allow their tissue sample(s) (even those taken prior to their participation in an SCRI-sponsored trial) to be used by the SCRI Oncology Research Consortium at some point in the future for testing and analysis of expression analysis and/or analysis of tumor markers. The registry will be contained in an electronic database, and will be sorted by disease indication. (Note: Patients will not be asked to return at a future date and have tissue samples collected; rather, SCRI will have the authorization to obtain pre-existing samples).

Observational
Observational Model: Cohort
Not Provided
Retention:   Samples With DNA
Description:

Potential retention of tissue blocks for future study.

Non-Probability Sample

The SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date.

  • Melanoma
  • Myelodysplastic Syndrome
  • Multiple Myeloma
  • Lymphoma
Other: Tissue Registry Study
If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.
1
The SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date.
Intervention: Other: Tissue Registry Study
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
20
February 2013
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must be >= 18 years of age.
  • Patients must be able to provide written informed consent.

Exclusion Criteria:

  • Not Applicable
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00965861
SCRI MISC 39
No
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Not Provided
Study Chair: Howard Burris, M.D. SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP